Abstract
The allocation of funding for new anticancer treatments within the UK has not kept pace with demand. Clinicians find themselves restricted in the use of licensed drugs which they feel are in the best interests of individual patients. Against this, health authorities have a duty to ensure that scarce resources are used equitably to meet the needs of the local population as a whole. Differential levels of funding for new treatments across the country have led to concerns about rationing by postcode. This paper outlines an approach to the prioritization of new treatment for advanced cancer developed jointly by clinicians and health authorities in South London. The approach involves evidence reviews and consensus meetings. Existing and new treatments are rated on a four-point ‘relative effectiveness scale’, which takes account of the impact of the treatment on quality of life and on survival. The strength of evidence supporting each effectiveness rating is also classified. Health Authorities have used these ratings to determine overall funding levels, while leaving decisions on individual patients to the relevant Trusts. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Fletchtner H, Filberti A, Fleishman SB and de Haes JC (1993) The European organisation for research and treatment of cancer QLQ-C30: A quality of life instrument for use in international trials in oncology. J Natl Cancer Inst 85: 365–376
Advanced Ovarian Cancer Trialists Group (1991) Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. BMJ 303: 884–893
Advanced Ovarian Cancer Trialists Group (1998) Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Br J Cancer 78: 1479–1487
Baum M, Priestman T, West R and Jones E (1980) A comparison of subjective responses in a trial comparing endocrine with cytotoxic treatment in advanced carcinoma of the breast. Proceedings of the Second EORTC Breast Cancer Working Conference, 223–226, Pergamon Press: Oxford
Cella DF, Tulsky DS, Gray G, Sarafin B, Linn E, Bonoma A, Silberman M, Yellen SB, Winicour P and Brannon J (1993) The Functional Assessment of Cancer Therapy Scale: development and validation of the general measure. J Clin Oncol 11: 570–579
Coates A, Gebski V, Bishop J, Jeal P, Woods R, Snyder R, Tattersall M, Byrne M, Harvey V, Gill G, Simpson J, Drummond R, Browne J, Van Cooten R and Forbes J (1987) Improving the quality of life during chemotherapy for advanced breast cancer: a comparison of intermittent and continuous treatment strategies. N Eng J Med 317: 1490–1495
de Haes JCJM, van Kippenberg FCE and Neijt JP (1990) Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer 62: 1034–1038
Department of Health (1996) Improving outcomes in breast cancer: The research evidence. Department of Health: London
Foy R, So J, Rous E and Scarffe JH (1999) Perspectives of commissioners and cancer specialists in prioritising new cancer drugs: impact of the evidence threshold. BMJ 318: 456–459
Glimelius B, Hoffman K, Olafsdottir M, Pahlman L, Sjorden P and Wennberg A (1989) Quality of life during cytostatic therapy for advanced symptomatic colorectal carcinoma: a randomised comparison of two regimens. Eur J Cancer Clin Oncol 25: 829–835
Gregory W, Smith P, Richards M, Twelves C, Knight R and Rubens R (1993) Chemotherapy of advanced breast cancer: outcome and prognostic factors. Br J Cancer 68: 988–995
Kaasa S, Mastekaasa A and Naess S (1988) Quality of life of lung cancer patients in a randomised clinical trial evaluated by a psychosocial well-being questionnaire. Acta Oncol 27: 335–342
Lilenbaum RC, Langenberg P and Dickersin K (1998) Single agent versus combination chemotherapy in patients with advanced non-small cell lung carcinoma. A meta analysis of response, toxicity and survival. Cancer 82: 116–126
Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311: 899–909
Ramirez AJ, Towlson KE, Leaning MS, Richards MA and Rubens RD (1998) Do patients with advanced breast cancer benefit from chemotherapy?. Br J Cancer 78: 1488–1494
Richards MA, Braysher S, Gregory WM and Rubens RD (1993) Advanced breast cancer: use of resources and cost implications. Br J Cancer 67: 856–860
Richards MA and Parrott JC (1996) Tertiary cancer services in Britain: benchmarking study of activity and facilities at 12 specialist centres. BMJ 313: 347–349
Secretary of State for Health (1997) The new NHS: Modern Dependable. HMSO: London
Silvestri G, Pritchard R and Welch HG (1998) Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 317: 771–775
Slevin ML, Stubbs L, Plant HJ, Wilson P, Gregory WM, Armes PJ and Downer SM (1990) Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses and general public. BMJ 300: 1458–1460
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Ferguson, J., Summerhayes, M., Masters, S. et al. New treatments for advanced cancer: an approach to prioritization. Br J Cancer 83, 1268–1273 (2000). https://doi.org/10.1054/bjoc.2000.1406
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1406
Keywords
This article is cited by
-
Biomarkers-Based Cost-Effectiveness of Toripalimab Plus Chemotherapy for Patients with Treatment-Naive Advanced Non-Small Cell Lung Cancer
Advances in Therapy (2023)
-
The Budget Impact of Monoclonal Antibodies Used to Treat Metastatic Colorectal Cancer in Minas Gerais, Brazil
Applied Health Economics and Health Policy (2021)
-
Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab
Applied Health Economics and Health Policy (2020)
-
Integrative Review of Managed Entry Agreements: Chances and Limitations
PharmacoEconomics (2020)
-
Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
BioDrugs (2018)